This company has been marked as potentially delisted and may not be actively trading. NASDAQ:REPH Recro Pharma (REPH) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Recro Pharma Stock (NASDAQ:REPH) Get Recro Pharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.47▼$2.1152-Week Range N/AVolume141,800 shsAverage Volume126,298 shsMarket Capitalization$117.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA. Read More Recro Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreREPH MarketRank™: Recro Pharma scored higher than 18% of companies evaluated by MarketBeat, and ranked 859th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Recro Pharma. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Recro Pharma are expected to grow in the coming year, from ($0.21) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Recro Pharma is -6.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Recro Pharma is -6.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for REPH. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRecro Pharma does not currently pay a dividend.Dividend GrowthRecro Pharma does not have a long track record of dividend growth. Sustainability and ESG3.8 / 5Environmental Score-1.12 Short InterestThere is no current short interest data available for REPH. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for REPH on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Recro Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders14.20% of the stock of Recro Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.34% of the stock of Recro Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Recro Pharma's insider trading history. Receive REPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recro Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. REPH Stock News HeadlinesFuji Pharma Co. Ltd.January 30, 2024 | wsj.comHere's what Wall Street expects from Recro Pharma's earnings reportNovember 7, 2023 | markets.businessinsider.comTesla to LEAVE the car market?Elon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corporate history. Tesla insiders are preparing for a dramatic new product launch – not driverless cars – that could change everything. You're running out of time to prepare.October 20 at 2:00 AM | Altimetry (Ad)US supreme court halts Purdue Pharma deal that shields Sacklers from lawsuitsAugust 16, 2023 | theguardian.comWhat Wall Street expects from Recro Pharma's earningsAugust 9, 2023 | markets.businessinsider.comMankind Pharma Ltd (MNKI)August 3, 2023 | investing.comBaudax Bio acquires Maryland biotechnology firm TeraImmune; stock jumpsJune 30, 2023 | bizjournals.comPomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Recro Pharma, Inc. Common Stock – SCTLJune 24, 2022 | benzinga.comSee More Headlines REPH Stock Analysis - Frequently Asked Questions How were Recro Pharma's earnings last quarter? Recro Pharma, Inc. (NASDAQ:REPH) issued its quarterly earnings data on Tuesday, March, 1st. The specialty pharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03. Recro Pharma had a negative trailing twelve-month return on equity of 56.66% and a negative net margin of 15.15%. What other stocks do shareholders of Recro Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Recro Pharma investors own include Corbus Pharmaceuticals (CRBP), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), SCYNEXIS (SCYX), Gilead Sciences (GILD) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings3/01/2022Today10/20/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:REPH CIK1588972 Webwww.recropharma.com Phone(770) 534-8239Fax484-395-2471Employees185Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.37 million Net Margins-15.15% Pretax Margin-15.09% Return on Equity-56.66% Return on Assets-11.14% Debt Debt-to-Equity Ratio2.27 Current Ratio3.24 Quick Ratio2.74 Sales & Book Value Annual Sales$75.36 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.90 per share Price / BookN/AMiscellaneous Outstanding Shares56,424,000Free Float48,412,000Market Cap$117.93 million OptionableOptionable Beta1.08 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:REPH) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...Brownstone Research | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recro Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recro Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.